BIOMAT Database Logo BIOMAT Database Logo

Diagnostic tests for rheumatoid arthritis: comparison of anti-cyclic citrullinated peptide antibodies, anti-keratin antibodies and IgM rheumatoid factors. 2002

S Bas, and T V Perneger, and M Seitz, and J-M Tiercy, and P Roux-Lombard, and P A Guerne
Division of Rheumatology, Department of Internal Medicine, University Hospital, Geneva, Switzerland.

OBJECTIVE To examine the value of anti-cyclic citrullinated peptide (anti-CCP) antibodies, anti-keratin antibodies (AKA) and immunoglobulin M rheumatoid factors (IgM RF) in discriminating between rheumatoid arthritis (RA) and other rheumatic diseases, and to determine whether the clinical manifestations or severity of erosions in RA are associated with anti-CCP positivity. METHODS In a cross-sectional study, we determined the concentrations or titres of these three markers in 179 RA patients and 50 controls. Erosions were quantified using the Larsen score in 129 patients. RESULTS Sensitivity was highest for IgM RF (75%), followed by anti-CCP antibodies (68%) and AKA (46%). Specificity was highest for anti-CCP antibodies (96%), followed by AKA (94%) and IgM RF (74%). A correlation with clinical manifestations and severity of erosions was observed mainly for IgM RF positivity. CONCLUSIONS With their excellent specificity, anti-CCP antibodies can be useful in establishing the diagnosis of RA, but IgM RF is a better predictor of disease severity.

UI MeSH Term Description Entries
D007075 Immunoglobulin M A class of immunoglobulin bearing mu chains (IMMUNOGLOBULIN MU-CHAINS). IgM can fix COMPLEMENT. The name comes from its high molecular weight and originally was called a macroglobulin. Gamma Globulin, 19S,IgM,IgM Antibody,IgM1,IgM2,19S Gamma Globulin,Antibody, IgM
D007633 Keratins A class of fibrous proteins or scleroproteins that represents the principal constituent of EPIDERMIS; HAIR; NAILS; horny tissues, and the organic matrix of tooth ENAMEL. Two major conformational groups have been characterized, alpha-keratin, whose peptide backbone forms a coiled-coil alpha helical structure consisting of TYPE I KERATIN and a TYPE II KERATIN, and beta-keratin, whose backbone forms a zigzag or pleated sheet structure. alpha-Keratins have been classified into at least 20 subtypes. In addition multiple isoforms of subtypes have been found which may be due to GENE DUPLICATION. Cytokeratin,Keratin Associated Protein,Keratin,Keratin-Associated Proteins,alpha-Keratin,Associated Protein, Keratin,Keratin Associated Proteins,Protein, Keratin Associated,alpha Keratin
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002956 Citrulline
D003430 Cross-Sectional Studies Studies in which the presence or absence of disease or other health-related variables are determined in each member of the study population or in a representative sample at one particular time. This contrasts with LONGITUDINAL STUDIES which are followed over a period of time. Disease Frequency Surveys,Prevalence Studies,Analysis, Cross-Sectional,Cross Sectional Analysis,Cross-Sectional Survey,Surveys, Disease Frequency,Analyses, Cross Sectional,Analyses, Cross-Sectional,Analysis, Cross Sectional,Cross Sectional Analyses,Cross Sectional Studies,Cross Sectional Survey,Cross-Sectional Analyses,Cross-Sectional Analysis,Cross-Sectional Study,Cross-Sectional Surveys,Disease Frequency Survey,Prevalence Study,Studies, Cross-Sectional,Studies, Prevalence,Study, Cross-Sectional,Study, Prevalence,Survey, Cross-Sectional,Survey, Disease Frequency,Surveys, Cross-Sectional
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000906 Antibodies Immunoglobulin molecules having a specific amino acid sequence by virtue of which they interact only with the ANTIGEN (or a very similar shape) that induced their synthesis in cells of the lymphoid series (especially PLASMA CELLS).

Related Publications

S Bas, and T V Perneger, and M Seitz, and J-M Tiercy, and P Roux-Lombard, and P A Guerne
[Diagnostic performance of anti-cyclic citrullinated antibodies and IgM rheumatoid factor in rheumatoid arthritis].
January 2007, Acta reumatologica portuguesa,
S Bas, and T V Perneger, and M Seitz, and J-M Tiercy, and P Roux-Lombard, and P A Guerne
[Anti-cyclic citrullinated peptide antibodies and rheumatoid arthritis].
May 2010, Rinsho byori. The Japanese journal of clinical pathology,
S Bas, and T V Perneger, and M Seitz, and J-M Tiercy, and P Roux-Lombard, and P A Guerne
Diagnostic value of anti-cyclic citrullinated peptide antibodies in rheumatoid arthritis.
August 2008, Saudi medical journal,
S Bas, and T V Perneger, and M Seitz, and J-M Tiercy, and P Roux-Lombard, and P A Guerne
Diagnostic performances of anti-cyclic citrullinated peptide antibodies in rheumatoid arthritis.
October 2007, Rheumatology international,
S Bas, and T V Perneger, and M Seitz, and J-M Tiercy, and P Roux-Lombard, and P A Guerne
[Anti-cyclic citrullinated peptide antibodies as a diagnostic test for rheumatoid arthritis].
March 2003, Harefuah,
S Bas, and T V Perneger, and M Seitz, and J-M Tiercy, and P Roux-Lombard, and P A Guerne
Anti-cyclic citrullinated peptide antibodies, IgM and IgA rheumatoid factors in the diagnosis and prognosis of rheumatoid arthritis.
May 2003, Rheumatology (Oxford, England),
S Bas, and T V Perneger, and M Seitz, and J-M Tiercy, and P Roux-Lombard, and P A Guerne
The diagnostic utilities of anti-agalactosyl IgG antibodies, anti-cyclic citrullinated peptide antibodies, and rheumatoid factors in rheumatoid arthritis.
March 2011, Rheumatology international,
S Bas, and T V Perneger, and M Seitz, and J-M Tiercy, and P Roux-Lombard, and P A Guerne
Diagnostic utility of anti-cyclic citrullinated peptide and anti-modified citrullinated vimentin antibodies in rheumatoid arthritis.
January 2008, Protein and peptide letters,
S Bas, and T V Perneger, and M Seitz, and J-M Tiercy, and P Roux-Lombard, and P A Guerne
Diagnostic utility of anti-cyclic citrullinated peptide antibodies for very early rheumatoid arthritis.
December 2006, The Journal of rheumatology,
S Bas, and T V Perneger, and M Seitz, and J-M Tiercy, and P Roux-Lombard, and P A Guerne
Anti-cyclic citrullinated peptide antibodies in advanced rheumatoid arthritis.
August 2003, Annals of internal medicine,
Copied contents to your clipboard!